microdose glp 1 menopause GLP-1 Microdosing During Menopause: Is it Right for You? Microdosing GLP 1 and the

The drug may cause changes in metabolic processes and hormonal levels that can activate coagulation pathways, increasing the tendency for blood to clot

Weight loss remains a central therapeutic driver: A reduction in body weight of at least 7 to 10 percent resolves NASH in approximately 65 to 90 percent of patients

Semaglutide remains one of the most effective options for patients searching for clinically supported Ozempic alternatives, especially when combined with professional oversight and lifestyle support

2 More detailed elucidation of the actions and benefits of GLP-1 medicines that might be partly independent of weight loss and glucose metabolism may provide new therapeutic opportunities to precisely target and further expand the use of GLP-1 therapeutics, perhaps, where weight loss may not be paramount, using lower doses that are less costly and associated with fewer adverse events

Genschmer KR, Russell DW, Lal C, et al

While we are optimistic for the remainder of the year, we recognize that medical and pharmaceutical cost trends remain volatile and will continue to present challenges, Marrone said